# ONC GENE INTRODUCTION AND EXPRESSION

> **NIH NIH R01** · UNIVERSITY OF PENNSYLVANIA · 1990 · $239,107

## Abstract

During the past five years we have been developing transgenic models of
oncogenesis and studying their characteristics.  In these experiments the
transforming oncogenes from simian virus 40 (SV40), activated ras, and
c-myc have been expressed in liver or pancreas to create several heritable
and predictable tumor phenotypes.  In these models at least one additional
event, the activation of another oncogenic element or the loss of a tumor
suppressor factor, appears to be necessary for final transformation to a
complete malignant phenotype.  Since the basic pattern of the premalignant
condition and eventual tumorigenesis is clearly defined in these unique
transgenic lines, other genes can now be introduced into mice and expressed
in transformed liver or pancreas to determine their influence on the course
of tumor formation and progression.  Several classes of genes believed to
be intricately involved in tumor development (e.g. growth factors,
proteases, and antioncogenes) are ideal candidates to study for their
effect on tumor phenotypes resulting from oncogenes.  Therefore, new lines
of mice will be generated that express these genes, and they will be
characterized and then crossed to lines of mice that show an
oncogene-induced phenotype.  The effect of expression of each gene on tumor
growth, invasion, and metastasis will then be assessed.  We have three
specific aims:

1.  We will determine if growth factors (including transforming factor
alpha, cholecystokinin, and angiogenin) influence the development and
progression of tumors induced by transgenic oncogenes.

2.  We will determine if proteases (including collagenase,
stromelysin/transin, and urokinase) enhance the invasive or metastatic
capability of tumors induced by transgenic oncogenes.

3.  We will determine if expression of "tumor suppressor" genes, (including
retinoblastoma and gap junction) interferes with the progression of tumors
induced by transgenic oncogenes.

## Key facts

- **NIH application ID:** 3176737
- **Project number:** 2R01CA038635-06
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **SAM.gov UEI:** GM1XX56LEP58
- **Principal Investigator:** Ralph Lawrence Brinster
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 1990
- **Award amount:** $239,107
- **Award type:** 2
- **Project period:** 1985-01-01 → 1994-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/3176737

## Citation

> US National Institutes of Health, RePORTER application 3176737, ONC GENE INTRODUCTION AND EXPRESSION (2R01CA038635-06). Retrieved via MORVS 2026-10-24 from https://api.morvs.ai/grant/nih/3176737. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*